DHODH and renal carcinoma: Intriguingly, CAD is also associated with unfavorable survival in liver cancer and renal cancer [13], and it catalyzes the rate-limiting step of the de novo PS pathway [14], suggesting it may be expressed at higher levels than DHODH and UMPS in de novo PS to ameliorate chemotherapy induced genotoxic damage.